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Hedgehog (HH) morphogen signalling, crucial for cell growth and tissue patterning in animals, is initiated by the binding of dually lipidated HH ligands to cell surface receptors.
Hedgehog-Interacting Protein (HHIP), the only reported secreted inhibitor of Sonic Hedgehog
(SHH) signalling, binds directly to SHH with high nanomolar afﬁnity, sequestering SHH. Here,
we report the structure of the HHIP N-terminal domain (HHIP-N) in complex with a glycosaminoglycan (GAG). HHIP-N displays a unique bipartite fold with a GAG-binding domain
alongside a Cysteine Rich Domain (CRD). We show that HHIP-N is required to convey full
HHIP inhibitory function, likely by interacting with the cholesterol moiety covalently linked to
HH ligands, thereby preventing this SHH-attached cholesterol from binding to the HH
receptor Patched (PTCH1). We also present the structure of the HHIP C-terminal domain in
complex with the GAG heparin. Heparin can bind to both HHIP-N and HHIP-C, thereby
inducing clustering at the cell surface and generating a high-avidity platform for SHH
sequestration and inhibition. Our data suggest a multimodal mechanism, in which HHIP can
bind two speciﬁc sites on the SHH morphogen, alongside multiple GAG interactions, to inhibit
SHH signalling.
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he Hedgehog (HH) morphogen pathway fulﬁls crucial
functions in growth and morphogenesis, whilst dysregulation leads to developmental disorders and cancer1–4. The
secreted N-terminal domain of SHH (ShhN) is generated from a
45 kDa precursor, undergoing intein-based cleavage to couple an
esteriﬁed cholesterol molecule to the C-terminus5. A subsequent
step involves the N-terminal attachment of a palmitoyl moiety to
produce the fully active lipid-modiﬁed signalling ligand (palmitoylated and cholesteroylated ShhN; pShhNc)6. Signalling is
activated by binding of pShhNc to the extracellular domains of
transmembrane protein PTCH1. Recent structural studies show
that PTCH1 and pShhNc form a 2:1 complex, with one molecule
of PTCH1 engaging pShhNc at a conserved high-afﬁnity interface
involving the conserved SHH zinc- and calcium-binding sites
(“protein-protein interface”), and the other at the terminal SHHpalmitoyl and -cholesteryl moieties (“lipid interface”)7–12. The
PTCH1:pShhNc interaction releases inhibition of the G-protein
coupled receptor Smoothened (SMO), which ultimately results in
activation of target genes via the GLI transcription factors2. When
no HH ligand is present, PTCH1 constitutively inhibits SMO
signalling, potentially by preventing access to cholesterol or a
similar sterol molecule10,13–16.
Extracellular distribution of pShhNc is key to the activation of
correct signalling responses. This is controlled by a combination
of co-receptor signalling17, the glycosaminoglycan (GAG) chains
of heparan sulphate proteoglycans (HSPGs)18,19 and the assembly
of pShhNc into multimers20,21. The HH pathway is modular, with
several other essential cell surface receptors alongside PTCH1.
For example, the immunoglobulin superfamily members CDO
and BOC bind directly to SHH via the conserved interface
involving the pShhNc metal-binding sites22–25. The metalbinding sites are also crucial for SHH interactions with the
vertebrate-speciﬁc HH antagonist Hedgehog-Interacting Protein
(HHIP)26,27. HHIP is the only secreted inhibitor of HH
signalling28–30, essential for the development of the lung31,
cartilage32 and brain33. HHIP downregulation is associated with
HH-dependent tumourigenesis34 and variants at the HHIP locus
are linked to Chronic Obstructive Pulmonary Disease (COPD),
one of the most common devastating lung diseases in humans35.
HHIP is composed of an N-terminal domain (HHIP-N) that
shows weak sequence homology to the cysteine-rich domain
(CRD) superfamily36, typically involved in small moleculebinding (Fig. 1a). The C-terminal domain of HHIP is composed of a β-propeller and two EGF repeats (HHIP-C). We and
others previously determined structures of HHIP-C in complex
with human HH ligands ShhN and DhhN, respectively26,27.
HHIP utilises a loop inserted into blade 3 of its β-propeller to
bind to the HH metal-binding site by directly coordinating the Zn
ion. This suggests that HHIP inhibits HH function by sequestering the HH morphogen, and acts as a decoy receptor. Our
recent study28 identiﬁed a role for HHIP—high afﬁnity interaction with the GAG chains of heparan sulphate proteoglycans
(HSPGs), as well as uncovering a cluster of residues in HHIP-N
involved in this process. However, the role of the HHIP-N CRD
and its potential small molecule binding properties remained
elusive.
In this work, we use a combination of structural, biophysical
and cellular studies to characterise the HHIP N-terminal region,
revealing an unexpected GAG binding domain and a CRD with a
small molecule-binding fold. We show that HHIP-N is necessary
to convey they full signal inhibition by HHIP in response to
pShhNc, and that the puriﬁed CRD binds to a mimic of the
cholesteroylated HH C-terminus. Importantly, we also identify
and structurally characterise two distinct GAG binding sites
within HHIP-N and HHIP-C, respectively, and show that HHIPC assembles into large HHIP-GAG oligomers. Our results reveal
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that HHIP uses a modular mechanism for SHH inhibition. HHIP
targets both the SHH metal-binding and lipid-modiﬁcation sites
recognised by PTCH1, while potentially staying localized on the
cell surface via HHIP-GAG interactions.
Results
Structure of the HHIP N-terminal domain reveals a CRD fold.
We expressed the N-terminal domain of HHIP (HHIP-N) using
mammalian expression in HEK293T cells37 (Fig. 1a). Puriﬁed
HHIP-N was crystallised in the presence of the GAG mimic
sucrose octasulphate (SOS). The structure of the HHIP-N:SOS
complex was determined using the single anomalous dispersion
(SAD) method from native sulphur atoms. A multi-crystal
approach was taken in which 24 data sets were collected from 8
isomorphous crystals, utilising both mini-kappa and inverse
beam strategies to maximise the observed anomalous signal
(Supplementary Table 1, Supplementary Fig. 1a–d)38,39. This
allowed us to determine the structure of HHIP-N in complex with
SOS at a resolution of 2.7 Å, with one molecule in the crystallographic asymmetric unit. HHIP-N possesses an elongated
globular fold with a unique N-terminal GAG-binding
domain (GBD) and a C-terminal CRD (Fig. 1b). HHIP-N is
stabilised by a total of 6 disulphide bonds. The GBD of HHIP-N
binds SOS, and contains a single helix and ﬂanking loop regions
(Fig. 1b, lower panel) that are stabilised by one intra-domain
disulphide bond (I: C39-78) and two inter-domain disulphide
bonds with helix α1 of the CRD (II: C69-C112 and III: C79-115).
The HHIP-N CRD is composed of 5 helices (α1-α5) stabilised by
three intra-CRD disulphide bonds (IV: C103-C152, V: C141-179
and VI: C145-168). All disulphide bonds were identiﬁed as
individual sites in the anomalous difference map, and treatment
of these as ‘super-sulphurs’ was vital for substructure determination and structure solution (Fig. 1c)40.
CRDs can bind to various small molecules, including folate
(folate receptors; FRα/β)41 and riboﬂavin (riboﬂavin-binding
protein; RFBP)42, as well as lipids and sterols, such as cholesterol
(SMO, NPC1)43,44 and palmitoleic acid (Frizzled; Fz)45. Previously, we performed an evolutionary structural analysis to
classify known CRDs into two distinct sub-families, containing
‘pockets’ or ‘grooves’ as ligand-binding elements46. In this
context, a ‘pocket’ refers to a CRD in which the ligand-binding
site consists of loops that fold over a deep cavity inaccessible to
solvent, whereas a ‘groove’ comprises a shallow and elongated
solvent-accessible binding cleft, which does not undergo major
conformational changes upon ligand binding. We have now
included our HHIP-N structure in this analysis and classiﬁed it as
a member of the pocket-type sub-family, with related structural
homologues in the CRDs of NPC1, RFBP and FRα/β (Fig. 1d,
Supplementary Table 2). Additionally, this analysis identiﬁes
sperm-egg fusion protein JUNO as being a pocket-type CRD
which has diverged from typical folate receptors47. The HHIP-N
CRD comprises a structural ‘scaffold’ composed of helices a1, a3
and a5 that are stabilised by disulphide bridges, a feature common
to all CRD family members (Fig. 1b, Supplementary Fig. 2). In
our HHIP-N structure, we observed two stretches of disordered
residues, which link the N-terminal domain and CRD helix α1
(DL1), and the loop regions between helices α2 and α3 (DL2),
respectively (Fig. 2a). In FRβ, the equivalent regions form the
majority of a folate-binding pocket (Fig. 2b), suggesting that DL1
and DL2 very likely occupy a similar region. The modes of ligand
binding by pocket-type CRDs are illustrated in Supplementary
Fig. 3b, c and Supplementary Fig. 3f, while ligand binding by
groove-type CRDs is detailed in Supplementary Fig. 3d-e. Helices
analogous to HHIP-N α1-5 form an equivalent ‘scaffold’ in
the pocket-type CRDs NPC1, RFBP and JUNO, within which
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Fig. 1 The structure of HHIP-N. a HHIP domain organisation and construct design. b Cartoon representation of HHIP-N in complex with SOS. In the top
panel, the CRD region is depicted in salmon and the N-terminal GAG-binding domain in dark blue. Two disordered loops (DL1 and DL2) are displayed as
dashed salmon lines. In the lower panel, the HHIP-N:SOS complex is shown in rainbow colouring (blue: N-terminus, red: C-terminus). The CRD helices are
labelled and disulphide bonds are numbered using Roman numerals. c Maps calculated from ﬁnal HHIP-N model. The 2Fo-Fc map is shown in blue,
contoured at 1σ. An anomalous difference map calculated from S-SAD data used for phasing is displayed as a yellow mesh contoured at 4σ. Corresponding
disulphide bonds are numbered using Roman numerals. d Structural phylogenetic analysis of CRDs (see Supplementary Table 2).

ligand-binding loops are positioned for small molecule binding. A
ligand-binding loop comparable to HHIP-N DL1 is also present
in the groove-type CRDs of Fz8 and SMO (Supplementary
Fig. 3d, e). This structural and evolutionary analysis suggests that
loops DL1 and DL2 could potentially form a binding pocket for a
physiologically-relevant small molecule ligand within the HHIPN CRD region.
Next, we tested the function of HHIP-N in a SHH signalling
assay, based on measuring the mRNA levels of the HH target
gene Gli1 in NIH/3T3 cells. We co-cultured PANC-1 human
pancreatic ductal adenocarcinoma cells expressing pShhNc48 to
activate the HH pathway. The puriﬁed full-length HHIP
extracellular domain only lacking the C-terminal helix (residues
39-670, HHIP-ΔHx, Fig. 1a) was able to inhibit HH signalling
more efﬁciently than HHIP-C (Fig. 2c), which lacks HHIP-N
but contains the high-afﬁnity SHH binding site26,27. We next
asked whether the interaction of HHIP-N with the SHH lipid
modiﬁcations could account for this increase of inhibition,
given the structural similarities with small molecule-binding

CRDs. For this, we activated the HH pathway with an
N-terminal palmitoylated-SHH peptide (Palm-ShhN15)49,
which does not interact with HHIP-C. In this context, HHIPΔHx was unable to inhibit signalling (Fig. 2d), excluding a role
of the SHH N-terminal palmitoyl moiety in HHIP-N binding.
We recently showed that the SHH C-terminal cholesterol
moiety is important for SHH-PTCH1 interactions and activation of HH signalling12. Using a similar isothermal titration
calorimetry (ITC) assay, we tested whether a PEGylated
cholesterol molecule (mimicking the C-terminus of pShhNc)
binds to HHIP. PEG-cholesterol bound speciﬁcally to HHIP-N
(KD = 23 µM) (Fig. 2e), whereas free PEG did not bind to
HHIP-N (Fig. 2f). Due to the high heat of dilution when PEGcholesterol is titrated into buffer, a series of controls were
conducted (Supplementary Fig. 4). Thermodynamic signature
plots for HHIP-N compare favourably with those obtained for
the recently published interaction of PEG-cholesterol with the
canonical Hh receptor PTCH112, revealing a high enthalpic
contribution to ΔG suggesting a hydrophobic interaction50.
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This supports that the interaction between PEG-cholesterol and
HHIPN is speciﬁc. Taken together, the enhancement of HH
signalling inhibition by HHIP in the presence of HHIP-N,
combined with structural homology to small molecule-binding
pocket-type CRDs and observed binding to PEG-cholesterol
suggests an interaction between HHIP-N and HH-linked
cholesterol. Hence, we propose a model whereby HHIP binds
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to SHH in a multimodal manner, utilising the SHH metalbinding sites for HHIP-C binding and potentially targeting the
cholesterol attachment site for HHIP-N binding. Such an
arrangement could be accommodated in a 1:1 SHH-HHIP
complex, as HHIP-N and HHIP-C are separated by a 25residue long, likely ﬂexible linker that could position the SHHlinked cholesterol to interact with HHIP-N and the SHH-metal
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Fig. 2 HHIP-N CRD contributes to HH signalling inhibition. a, b Structural homology of HHIP-N with CRDs suggests small molecule interaction. HHIP-N
(a) is shown, with missing loops DL1 and DL2 displayed as green dashed lines and helices are annotated α1-5. A potential ligand-binding pocket is outlined
with a dashed circle. FRβ (b) binds a folate molecule (spheres, circled), utilising loops structurally analogous to HHIP-N DL1 and DL2 (coloured green).
Helices are annotated α1-5 as in HHIP-N. c RT-PCR assay from NIH/3T3 cells co-cultured with PANC-1 cells expressing pShhNc to quantify Hh signalling in
the presence of HHIP constructs. Relative levels of Gli1 mRNA were quantiﬁed and normalised from 5 independent experiments and displayed as mean
values ± SEM, with statistical signiﬁcance calculated using a two-tailed, paired t-test with p = 0.0091. d HH signalling assay to assess HHIP-ΔHx inhibition
of pathway activation in response to a palmitoylated N-terminal pShhNc peptide. e Raw ITC (upper panel) and binding isotherm (lower panel) for titration
of PEG-cholesterol into HHIP-N. f Raw ITC (upper panel) and binding isotherm (lower panel) for titration of unconjugated PEG200 into HHIP-N. Source
data are available as Source Data ﬁle.

binding site to interact with HHIP-C within the same molecule
(Supplementary Fig. 5).
The HHIP N-terminal domain contains a GAG-binding
domain. To shed light onto the previously reported GAGbinding properties of HHIP-N28, we determined structures of apo
and SOS-bound HHIP-N to resolution of 2.6 Å and 2.7 Å,
respectively (Supplementary Table 1). In the apo HHIP-N
structure, the N-terminal GAG-binding domain is disordered,
while the CRD region is inherently structured (Fig. 3a). This
suggests that interaction of HHIP-N with GAG molecules triggers
a transition to a folded state, forming an α-helix between residues
50 and 58. Each HHIP-N molecule interacts with 3 SOS molecules (Fig. 3b, Supplementary Fig. 6). SOS is bound to a positively
charged surface localised to the HHIP-N N-terminal domain
(Fig. 3c), forming electrostatic interactions with a cluster of 6
basic residues and burying a total surface area of 594 Å2 (Fig. 3d).
Only Arg-47 forms hydrogen bonds with more than one SOS
molecule; Arg-51 and Arg-54 are the only residues within the
N-terminal α-helical residues 50–58 to contact a SOS molecule.
Mutagenesis of SOS-interacting basic HHIP residues (marked
with asterisks in Fig. 3d) were previously observed to weaken the
interaction between HHIP and heparin, validating our observed
HHIP-N:SOS interface28. The N-terminal domain of HHIP-N is
different compared to other structurally characterised CRDs,
having evolved a GAG-binding function in a discrete domain
alongside a conserved small molecule-binding fold. Additionally,
we report structural insights into the major secondary structural
rearrangements of HHIP-N, a GAG-binding protein, upon sugar
coordination.
Structure of the HHIP C-terminal domain in complex with
heparin. Our previous analysis of HHIP:GAG interactions
identiﬁed multiple GAG-binding motifs in HHIP, since a construct that contains a deletion of HHIP-N was still able to bind to
heparin27. To decipher the GAG-binding properties of HHIP, we
conducted binding assays using three domain deletion constructs
(Fig. 1a). First, we tested GAG binding using heparin afﬁnity
chromatography (Fig. 3e). Both HHIP-C and HHIP-N show
binding to a heparin column, albeit with weaker afﬁnity when
compared to HHIP-ΔHx. Furthermore, HHIP-N, HHIP-C and
HHIP-ΔHx are all cell surface-associated at physiological pH and
ionic strength (Supplementary Fig. 7). Taken together, our analysis suggests that both HHIP-N and HHIP-C contribute to the
observed afﬁnity for GAG chains.
To structurally characterise HHIP-C:GAG interactions, we
determined the 2.7 Å resolution crystal structure of HHIP-C in
complex with a 30-mer heparin molecule (Supplementary Table 1,
Supplementary Fig. 8a). HHIP-C comprises an N-terminal 6bladed β-propeller and 2 C-terminal EGF repeats, previously
identiﬁed in the complex of HHIP-C with HhN ligands26,27. The
heparin chain contacts two separate clusters of HHIP surface
residues (GAG ‘site1’ and GAG ‘site 2’) at either end of the

molecule (Fig. 4a, Supplementary Fig. 8). In this arrangement, a
HHIP-C anti-parallel dimer coordinates one single heparin chain
(Fig. 4b) by using a central positively-charged region formed by
residues from both HHIP protomers (Fig. 4c). The HHIP-C
chains in the dimer are essentially identical (r.m.s.d. of 0.21 Å for
322 equivalent Cα atoms), and show little structural difference to
previously published HHIP-C structures (e.g. r.m.s.d. of 0.31 Å
for 331 equivalent Cα atoms, PDB ID. 2WFT26). The heparin
backbone displays a right-handed helical structure with roughly
4 sugars per turn, in agreement with previous structural
studies51,52. A total of 8 monosaccharides are resolved in the
structure, running from a reducing (O1; sugar I) to a nonreducing end (O4; sugar VIII) and forming hydrogen bonds with
several polar side chains (Fig. 4d). We also determined the crystal
structure of a HHIP-C:SOS complex, which exhibits the
equivalent anti-parallel, dimeric HHIP arrangement bound to
two SOS molecules coordinated at the same site compared to
heparin (Supplementary Table 1, Supplementary Figs. 8b, 9 and
10). In summary, our HHIP-C crystal structures in complex with
GAG molecules identify two discrete GAG-binding sites on the
surface of HHIP-C, which are distinct and non-overlapping with
the HhN-binding interface (Fig. 4e), thus suggesting that both
GAG- and HhN-binding can occur simultaneously.
GAG interactions control oligomerisation of HHIP. Our previous study on HHIP:GAG interactions identiﬁed low micromolar afﬁnities for the interactions between HHIP-C and the
GAGs heparin, heparan sulphate (HS) and chondroitin sulphate
(CS)28. To experimentally validate our HHIP-C:GAG complex
structures, we generated a HHIP mutant in which 6 positivelycharged residues involved in GAG recognition were mutated to
glutamate (K277E/R328E/R350E/K569E/R610E/R613E, HHIP-C
Glu mutant; Fig. 4d) and analysed binding to GAGs. Using surface plasmon resonance (SPR) with GAGs immobilised on the
chip, we observed that the HHIP-C Glu mutant almost completely abolishes binding to heparin, HS and CS, when compared
to wild-type (HHIP-C WT) (Fig. 5a). Furthermore, we analysed
our observed HHIP-C:GAG interfaces by a combination of
mutagenesis and heparin afﬁnity chromatography. In addition to
the HHIP-C Glu mutant, we generated glycosylation mutants
(Supplementary Fig. 10a). N-linked glycans were inserted into the
GAG-interacting surfaces of either the HHIP β-propeller (‘ΔGAG
site 1’) or EGF repeats (‘ΔGAG site 2’), as well as combination of
both (‘ΔGAG sites 1 + 2’). As expected, all mutants showed
reduced heparin binding afﬁnity relative to HHIP-C WT (Supplementary Fig. 11b). Next, we tested the effect of HHIP-C WT or
HHIP-C Glu mutant in SHH signalling assays using NIH/3T3
cells (Fig. 5b). We observed that the HHIP-C Glu mutant showed
signiﬁcantly less efﬁcient SHH inhibition. To further probe
whether this effect results from loss of GAG-binding, we knocked
out EXTL3, a key enzyme in the biosynthesis of cell-surface
heparan sulphate (HS) chains (Supplementary Fig. 12a–d)53. We
conﬁrmed that single Extl3−/− NIH/3T3 clones lack surface HS
chains by showing markedly reduced binding to a scFv antibody
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shown as sticks. e Comparison of heparin (yellow sticks) and HhN (orange cartoon) interaction sites on HHIP-C electrostatic surface.
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Fig. 5 Analysis of HHIP-C:GAG interactions and oligomerisation. a Comparative SPR curves for HHIP-C WT (light blue) and HHIP-C Glu mutant (red)
binding to heparin, heparan sulphate (HS) and chondroitin sulphate (CS); b Quantiﬁcation of HH pathway inhibition with the addition of HHIP-C WT or
HHIP-C Glu mutant. Relative levels of Gli1 mRNA were quantiﬁed from 10 independent experiments, with statistical signiﬁcance calculated using a twotailed, paired t-test with p = 0.045; Data are presented as mean values ± SEM. c Model for cell surface HHIP-C oligomeric assembly. GAG chains
(represented by heparin, yellow) stabilise a core anti-parallel HHIP-C dimer (surface; black and white) and can then recruit further HHIP-C chains (light
blue, violet) to form long oligomeric chains. This facilitates binding and antagonism of multiple HhN ligands (orange). d, e AUC experiments to assess
the oligomerisation of HHIP in solution, comprising HHIP-C (d) and HHIP-C:heparin 30-mer complex (e); f, g As in (c, d), comprising HHIP-C Glu mutant
(e) and HHIP-C Glu mutant mixed with 30-mer heparin (f). Source data are available as Source Data ﬁle.

(HS20) that is known to recognize multiple HS chains54,55
(Supplementary Fig. 12e). These Extl3−/− clones were responsive
to SHH, showing that the machinery required to receive and
respond to ligands was unaffected by the loss of HS chains
(Supplementary Fig. 12e). Compared to their individual level of
SHH activation, wildtype HHIP was a less effective inhibitor in
both knock-out cell lines than in their parental cell line. Even
more importantly, both HHIP wildtype and Glu mutant inhibited
the HH response in the HS-deﬁcient cells to similar degrees, in
contrast to the parental cell line where Glu mutant HHIP was a
less effective inhibitor (Supplementary Fig. 12e). This demonstrates that the interaction between HHIP-C and GAGs are critical for maximal HH pathway inhibition.
Our HHIP-C:heparin complex structure also suggests that GAGs
can mediate the formation of long oligomeric chains of HHIP
(Fig. 5c). We observe two HHIP oligomerisation interfaces - an
anti-parallel ‘head-to-tail’ heparin-bound HHIP-C dimer (Supplementary Fig. 13a) with a total buried surface area of 603 Å2
(Supplementary Fig. 13a), and a ‘head-to-head’ dimer with a buried
surface area of 981 Å2 (Supplementary Fig. 10b) in the crystal. The
‘head-to-tail’ dimer interface is smaller than physiological dimer
interfaces and is likely stabilised by the heparin molecule (PISA ΔiG
8

P-value = 0.41, shape complementarity score = 0.75)45,46, while the
larger ‘head-to-head’ interface is more likely to be physiological
(PISA: ΔiG P-value = 0.43, shape complementarity score: 0.52).
Previous studies using multi-angle light scattering (MALS) showed
that the apo HHIP-C is monomeric at a concentration of
approximately 10 μM26. To test whether oligomers observed in
the crystal structure exist in solution at higher concentrations
(potentially mimicking the local concentrations at the cell
membrane), we performed sedimentation velocity analytical
ultracentrifugation experiments (AUC). This revealed a predominantly monomeric apo HHIP-C population (4 S, 53 kDa), with
minor populations of dimers (5 S, ~100 kDa) and trimers (6 S,
~150 kDa) also observed (Fig. 5d). As expected, addition of the
heparin 30-mer triggers a drastic shift to increased sedimentation
rates, and causing the sedimentation of an array of higher-order
oligomeric species from 50 kDa up to 6 MDa (4 S–50 S; Fig. 5e).
Higher-order oligomer formation in response to the addition of
heparin is completely ablated in the HHIP-C Glu mutant (Fig. 5f±g),
consistent with GAG-binding induced oligomerisation of HHIP.
Taken together, our biophysical and cellular data suggest that
HHIP:GAG complexation leads to HHIP clustering, and these
assemblies might ﬁne-tune inhibition of the HH signal.
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Fig. 6 Models of extracellular HH signalling antagonism by HHIP. a A 2:1
interaction of PTCH1:pShhNc represents the active signalling complex. The
pShhNc lipid appendages insert to seal channels in PTCH1-B. b HHIP-C
targets the conserved high-afﬁnity metal ion-binding site on the pShhNc
surface (‘protein-protein interaction’), competing with binding from PTCH1A and other co-receptors, whilst HHIP-N is able to contribute to this by
targeting the C-terminal cholesterol moiety, possibly re-establishing PTCH1
cholesterol transport ability. It is also of note that HH signalling is activated
via SMO CRD-cholesterol interaction, and competition of this by the HHIPN CRD represents a possible additional mode of inhibition. Additionally,
HHIP-mediated receptor endocytosis may act to remove SHH from the cell
surface. c Cell surface GAG-mediated clustering represents a second
modality for HH regulation by HHIP. The avidity of HHIP is increased by
cluster formation at the proteoglycan layer, similar to how SHH lipoprotein
multimers act to increase local morphogen concentration. The GAGbinding site in HHIP-N is also important for this process.

HHIP-N can also bind GAGs with high afﬁnity and despite
crystallising as a monomer, forms weak dimers in solution when
analysed using MALS (Supplementary Fig. 14a). Interestingly,
apo HHIP-N is predominantly monomeric in solution up to
200 µM when studied by AUC (Supplementary Fig. 14b), and can
also form oligomers in the presence of heparin (up to a size
consistent with tetramers, as shown from c(s, f/f0) plots to analyse
molecular weights in solution; Supplementary Fig. 14c). This is
consistent with our crystal packing analysis (Supplementary
Fig. 4), and suggests that GAGs stabilise a contact between HHIPN GAG-binding domains in solution to assist oligomerisation
(Supplementary Fig. 14d). In conclusion, HHIP is regulated
through both protein:protein- and protein:GAG-mediated oligomerisation at several different sites, that can be linked to dynamic
modulation of HH signalling.
Discussion
The function of the N-terminal domain of HHIP has remained a
long-standing mystery. Previous work in our laboratory and by
others showed that HHIP-C binds to the metal-binding site of
SHH with high (low nanomolar) afﬁnity, and inhibits HH signalling by functioning as a decoy receptor26. Our structural,
biophysical and cellular work reveals that HHIP-N contains a
CRD, which acts as an additional module within HHIP to inhibit
HH signalling. Moreover, HHIP-N has evolved a structured
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region engaged in cell surface heparan sulphate proteoglycan
binding. Recent pioneering work on the PTCH1:pShhNc interaction has greatly enhanced our understanding of HH signal
reception and transduction. PTCH1 and SHH interact in a
2:1 stoichiometry, with one PTCH1 molecule (PTCH1-A) binding to the high-afﬁnity metal-binding site of SHH and the other
PTCH1 molecule (PTCH1-B) grasping the two lipid modiﬁcations to form the full signalling complex (Fig. 6a). None of these
interactions alone is sufﬁcient to fully inactivate PTCH1 function
in cellular assays12. This mechanism shows parallels to WNT
morphogen signalling, in which WNT interacts with its receptor
Frizzled (Fz) with both its covalently-linked palmitoleate (via the
Fz-CRD, evolutionarily related to the HHIP-N CRD), and also via
a protein-protein interface45. WNT inhibition is, in part, achieved
by interactions with secreted Fz-related proteins (sFRPs) (via
both palmitoleate- and protein-protein contacts), which act as
secreted decoy receptors56. Our structural and functional analysis
suggests that HHIP has potentially evolved a similar role, targeting the SHH cholesterol moiety (via HHIP-N) and the metalbinding site (via HHIP-C). Thus, a two-pronged engagement with
both protein- and lipid-based interfaces seems to be a common
theme in recognition of morphogens.
Insertion of the SHH palmitoyl and cholesteryl moieties into
the ectodomain of PTCH1-B blocks a proposed conduit for
cholesterol/sterol transport57,58. Shielding of the pShhNc cholesterol modiﬁcation by HHIP-N would be an effective
mechanism to release SHH-mediated inhibition and transport
function of PTCH1. This is complemented by HHIP-C and
PTCH1-A competing for the SHH metal-binding site, which also
overlaps with the binding sites for co-receptors CDO, BOC and
GAS117,22. These two modes of signal antagonism constitute a
fail-safe mechanism by which HHIP regulates HH signalling.
HHIP-C binds to the SHH metal-containing site some 100-fold
tighter compared to CDO22,26 and PTCH112, and thus could
outcompete both CDO and PTCH1 from this site. This could
result in the formation of a ‘negative receptor complex,’ facilitating for example SHH endocytosis (Fig. 6b).
Various studies have identiﬁed HHIP as the only known
secreted diffusible inhibitor of HH signalling28,29,59. We previously showed that HHIP secretion is dependent on interaction
with GAGs, and that HHIP can bind to various types of GAGs28.
Here, we have delineated the molecular basis for this interaction.
Both HHIP-N and HHIP-C contain discrete GAG-binding sites,
which combine to modulate cell surface afﬁnity. Together, they
constitute additional minor regulatory sites of HH signalling. Cell
surface-attached GAGs such as HS and CS organise secreted
proteins into gradients, varying local concentrations to enable
graded signal activation60. Here, we show that GAGs are able to
cluster HHIP-C into large assemblies, linked to the potency of
HHIP-mediated HH inhibition (which is further potentiated by
HHIP-N). In addition, the HHIP C-terminal helix (residues
671–700) that contributes to cell surface binding via formation of
a predicted leucine zipper-type assembly28 may enhance clustering even further, combined with the dimerisation abilities
observed for both HHIP-N and HHIP-C. HHIP clustering by
GAGs at the cell surface generates a high-avidity platform for
SHH binding. This platform might limit diffusion and loss of
HHIP into extracellular space and position HHIP to inhibit SHH
signalling at the cell surface (Fig. 6c). This process can be further
regulated by SHH-mediated internalisation of HHIP29, which
potentially can happen at both SHH producing or responding
cells. From our structural analysis, we also note that there is a
long ﬂexible linker between HHIP-N and HHIP-C, which we
previously described as being proteolytically sensitive26. Cleavage
of this linker may regulate the overall cell surface afﬁnity of HHIP
in vivo. Taken together, our results indicate that HHIP regulation
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of HH signalling is dynamic, and inhibitory processes are modularised through distinct functionalities within the HHIP N- and
C-terminal domains.
Aberrant expression of SHH has been linked to the initiation
and progression of numerous cancers, and HH inhibitors targeting SMO are in the clinic against basal cell carcinomas3,4. The
SHH-speciﬁc mouse antibody 5E1 binds tightly to the SHH
metal-binding site, overlapping with HHIP61, and has been
shown to inhibit SHH activity in vivo and to reduce tumour
growth in a pancreatic cancer mouse model62. HHIP could be
used in a similar way, working as an engineered biologic to inhibit
HH signalling. Here, we provide the framework for the development of HHIP-based HH inhibitors that can speciﬁcally preserve or block the different SHH-receptor interaction sites, and
this interaction mode can be further ﬁne-tuned by the GAGbinding properties and resultant HHIP clustering. Various
biomedically-important secreted signalling proteins are reported
to undergo GAG-dependent clustering63, and drugging such
mechanisms could present an unexploited avenue for therapeutic
discovery.
Methods
Protein expression and puriﬁcation. Constructs of human HHIP (UniProt ID:
Q96QV1) comprising the N-terminal domain (HHIP-N, 39-209), C-terminal
domain (HHIP-C, 213-670)26 and a full-length variant only lacking the C-terminal
helix (HHIP-ΔHx; 39-670) were cloned in the pHLsec vector in frame with a
C-terminal His6-tag37. Additionally, HHIP-ΔHx was designed to contain a stabilised linker between HHIP-N and HHIP-C, comprising 7 point mutations (R185A,
K186A, R189A, K204A, R210A, K211A and K213A) (see Supplementary Table 3
for used primers). This was performed to prevent interdomain proteolysis, as was
observed previously for HHIP-ΔHx constructs26,27. HHIP constructs were
expressed by transient transfection in HEK293T cells following a similar procedure
as described in26. Brieﬂy, HEK293T cells were grown in expanded-surface polystyrene roller bottles (2125 cm2, Greiner Bio-One). Per roller bottle, a transfection
cocktail was prepared by incubating 1 mL of 1 mg mL−1 25 kDa branched polyethylenimine (Sigma Aldrich) with 0.5 mg plasmid DNA in 50 mL serum-free
DMEM for 10 min at room temperature. Prior to addition of the cocktail to the
cells, the mixture was supplemented with 1 µg mL−1 ﬁnal concentration of the
glycosylation inhibitor kifunensine64. Proteins were then expressed for 3–5 days in
DMEM supplemented with 2% (v/v) FBS and 2 mM L-Glutamine/non-essential
amino acids. Conditioned medium was dialysed against PBS and proteins were
isolated via immobilised metal-afﬁnity chromatography using a HisTrap HPTM
column (GE Healthcare). All proteins were subsequently puriﬁed further via size
exclusion chromatography in a buffer of 10 mM HEPES pH 7.5, 150 mM NaCl. In
the case of HHIP-N and HHIP-ΔHx, a further puriﬁcation step utilising a HiTrap
Heparin HPTM (GE Healthcare) column was added to remove co-eluting degradation products.

Diffraction data were collected at a temperature of 100 K with crystals mounted
within a liquid N2 cryo-stream. Crystals were treated with an appropriate
cryoprotectant supplemented with reservoir solution (HHIP-N:SOS, 15% glycerol;
apo HHIP-N, 30% ethylene glycol; HHIP-C:heparin, 30% ethylene glycol; HHIPC:SOS, 20% glycerol) and ﬂash-cooled in liquid N2 prior to data collection. Data
were collected at Diamond Light Source, UK on beamlines I03 (HHIP-C:heparin,
λ = 0.97631 Å), I04 (HHIP-N:SOS; HHIP-C:SOS, λ = 0.97949 Å) and I24 (apo
HHIP-N, λ = 0.96862 Å). Data collection of HHIP-N for experimental phasing by
the Sulphur-Single Anomalous Dispersion (S-SAD) method was carried out at
λ = 1.7712 Å. This wavelength was selected to maximise the observed anomalous
signal without compromising the transmission of X-rays66. To counteract the low
anomalous signal from S atoms at this wavelength, S-SAD data collection of HHIPN:SOS crystals was performed using inverse beam (I03) and mini-kappa
goniometry-based (I04) approaches38,39. A total of 24 datasets on 8 different
crystals were collected. In all other cases, data were collected using the standard
rotation method. Diffraction data were scaled and merged using XIA267–72. The
HHIP-C:heparin complex data was processed using the program DIALS in
combination with XIA273. In all cases, an inner shell with a CC1/2 of 0.30 was
utilised in the selection of a high-resolution cut-off74.
Structure solution. We determined the structure of the HHIP-N:SOS complex by
S-SAD phasing. The sulphur substructure was determined using the HKL2MAP
interface for the SHELX suite75,76. Using SHELXC, an anomalous signal to 4 Å
resolution was observed, and searching for 6 sulphur sites as disulphides in
SHELXD gave a solution with CCweak and CCall statistics of 23.8 and 42.4
respectively. These SHELXD substructure coordinates were used as input ﬁles for
an initial round of phasing in Phenix Autosol and Autobuild pipelines77,78. This
enabled determination of a partial HHIP-N structure, with 87 of 182 residues built
(Supplementary Fig. 1a). This partial model was then used as input for Molecular
Replacement-SAD in Phaser79. This allowed extension of the model to 98 residues
placed in the asymmetric unit (Supplementary Fig. 1b). Manual building in Coot80
and initial reﬁnement in Refmac581 enabled the tracing of 110 residues, also
resulting in visible electron density for a SOS molecule (Supplementary Fig. 1c).
The HHIP-N SOS complex was reﬁned using iterative cycles of reﬁnement in
BUSTER 2.10.382 and Phenix83 (Supplementary Fig. 1d). Calculation of an
anomalous difference map for the ﬁnal HHIP-N:SOS structure identiﬁed 6 peaks at
4σ, corresponding to the 6 disulphide bonds (Supplementary Fig. 1e). The apo
HHIP-N structure was solved by molecular replacement using the HHIP-N:SOS
complex as a search model in Phaser84 and subsequently reﬁned using Phenix83.
Both the HHIP-C:heparin and HHIP-C:SOS complexes were solved by
molecular replacement using the HHIP-C apo-structure (PDB ID: 2WFT; residues
213-670)26 as a search model in Phaser75. The HHIP-C:heparin complex was
reﬁned using Buster 2.10.382, and HHIP-C:SOS with Phenix83. For the HHIPC:heparin complex, 8 sugars were accounted for by the electron density per
asymmetric unit. Restraints were generated for both pyranose constituents (IDS,
SGN) of heparin using the program Privateer85. For the HHIP-C:SOS complex, 2
SOS molecules were visible in the electron density per HHIP-C chain (2 HHIP-C
chains per asymmetric unit).

Heparin afﬁnity chromatography. Puriﬁed HHIP constructs were loaded onto a
1 mL Heparin column (HiTrap Heparin HP: Life Technologies) equilibrated in
20 mM NaCl, 10 mM HEPES pH 7.5 (~3 mS/cm). Constructs were eluted over 20
column volumes using a linear gradient of elution buffer up to 1000 mM NaCl,
10 mM HEPES pH 7.5 (~85 mS/cm). The elution of HHIP constructs was followed
via absorption at 280 nm. HHIP-N elutes at 520 mM NaCl, 10 mM HEPES pH 7.5
(~44 mS/cm), HHIP-C at 480 mM NaCl, 10 mM HEPES pH 7.5 (~41 mS/cm) and
HHIP-ΔHx at 590 mM NaCl, 10 mM HEPES pH 7.5 (~50 mS/cm).

Structure analysis. Stereochemical properties were assessed using the MolProbity
server86. Surface electrostatic potentials were generated using APBS87. Superpositions were calculated using PYMOL (www.pymol.org), which was also used to
generate ray-traced images of protein structures for ﬁgures. Residues involved in
interactions were identiﬁed using both the PDBSUM and PISA servers88,89. The
solvent accessible radius was set to 1.4 Å for the representation of all protein
surfaces. Structural evolutionary analysis of CRDs was performed using SHP90,91
and PHYLIP92 to assemble a phylogenetic tree (Supplementary Table 2). Structurebased sequence alignments of HHIP-N with evolutionarily-related CRDs were
generated using UCSF Chimera93 and were prepared for publication using the
program Aline94. Carbohydrate stereochemistry was validated with Privateer85.

Crystallisation and data collection. Prior to crystallisation trials, proteins were
concentrated via ultraﬁltration (HHIP-N, 6.8 mg mL−1; HHIP-C, 7.0 mg mL−1)
and deglycosylated by addition of catalytic quantities of endoglycosidase F164 at a
ratio of 1:250 (w/w) (HHIP:EndoF1). For HHIP co-crystallisation with GAGs,
either 10 mM SOS (Toronto Research Chemicals) or 1.5 mM 30-mer heparin
(Iduron) was added to the concentrated protein. Nanolitre-scale crystallisation
trials were performed using a Cartesian Technologies robot (100 nL protein plus
100 nL reservoir solution) in 96-well Greiner plates65. The HHIP-N:SOS complex
was crystallised in 0.1 M imidazole/MES pH 6.5, 0.1 M carboxylic acids (0.02 M
sodium formate, 0.02 M ammonium acetate, 0.02 M sodium citrate, 0.02 M sodium
oxamate and 0.02 M potassium sodium tartrate), 10% w/v PEG 20000 and 20% v/v
PEG MME 550; apo HHIP-N was crystallised in 0.1 M HEPES pH 7.0, 0.2 M
ammonium chloride, 0.02 M hexamine cobalt (III) chloride, 0.002 M SOS and 20%
w/v PEG 6000. The HHIP-C:heparin complex was crystallised in 0.1 M bis-Tris pH
6.5, 0.2 M sodium citrate and 20% w/v PEG 3350; the HHIP-C:SOS complex was
crystallised in 0.1 M Tris/Bicine pH 8.5, 0.03 M magnesium chloride, 0.03 M calcium chloride, 10% w/v PEG 20 000 and 20% v/v PEG MME 550. All crystals of
HHIP were grown at 20 °C.

Analytical ultracentrifugation (AUC). For AUC experiments HHIP-N and
HHIP-C were dialysed into 10 mM HEPES pH 7.5, 120 mM NaCl. Experiments
were performed at 20 °C using a Beckman Optima XL-I analytical ultracentrifuge
(Beckman Instruments) with absorbance optics at 280 nm and interference optics.
HHIP-N samples were spun at a concentration of 0.7 mg mL−1, alone and with the
addition of 0.09 mM 30-mer heparin (dp30, Iduron). HHIP-C samples were spun
at a concentration of 1 mg mL−1, alone and with the addition of 0.16 mM 30-mer
heparin (dp30, Iduron). As a control, heparin was spun alone in a separate
chamber at the concentration speciﬁed and analysed using interference optics.
Samples were contained within 12 mm Epon sector-shaped two-channel centerpieces and spun at 128,794 × g (An60Ti rotor, Beckman Coulter Inc., CA), with
80 sample distribution scans taken in 6 min intervals, alongside interference optics.
Absorbance data for scans 5–50 were analysed using the program SedFit for sizeand-shape distributions c(s) and (c(s,fr), where fr is the frictional ratio and for a
sphere fr = 1 and for other species fr > 1)95. This enables the plotting of contour
plots of c(s,M), where M is the weight of the protein. Due to the complex distributions observed in the case of HHIP-C:heparin, we present only c(s) distributions for HHIP-C experiments. For full clarity of solution molecular weights,
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c(s, fr) distributions were calculated for HHIP-N. In all cases, a partial speciﬁc
volume value of 0.73 mL g−1 was used.
Surface plasmon resonance. SPR experiments were performed using a Biacore
T200 machine (GE Healthcare) in 10 mM HEPES pH 7.5, 120 mM NaCl, 0.05% (v/
v) polysorbate 20, at 25 °C. Proteins were buffer exchanged into running buffer and
concentrations were calculated from the absorbance at 280 nm using predicted
molar extinction coefﬁcient values. Heparin (Iduron; average molecular weight
>9000 Da), heparan sulphate (HS) from porcine mucosa (Iduron) and chondroitin
sulphate (CS) sodium salt from shark cartilage (Sigma) were biotinylated using EZlink Biotin-LC-Hydrazide (Thermo Fisher Scientiﬁc) in a solution containing 17%
(v/v) DMSO for 26 hours at 20 °C. GAGs were then extensively dialysed, ﬁrst
against water and then SPR running buffer (120 mM NaCl, 10 mM HEPES pH 7.5,
0.05 % v/v Tween 20), similar to a procedure described previously96. Biotinylated
sugars were immobilised on CM5 sensor chips to which 3000 RU of streptavidin
were covalently coupled97. After each binding experiment, the chip was regenerated with running buffer supplemented with 1.5 M NaCl at 30 μL min−1 for 120 s.
In all experiments, the trace returned to baseline following regeneration. HHIP
constructs were injected at a ﬂow rate of 5 μL min−1. All data were analysed using
SCRUBBER2 (Biologic) and GraphPad Prism Version 6.04 (GraphPad Software, La
Jolla California USA). Best-ﬁt binding curves were calculated using non-linear
curve ﬁtting of a one-site–total binding model (Y = [Rmax*X/(KD + X)] +
NS*X + Background], where X is analyte concentration and the level of nonspeciﬁc binding is assumed to be proportional to the analyte concentration; hence
NS equals the slope of non-speciﬁc binding). The background value was set to zero
as the data had been previously referenced. Rmax and KD values quoted are
determined for the speciﬁc binding portion only.
Isothermal titration calorimetry. Experiments were performed using a MicroCal
PEAQ-ITC (Malvern) at 25 °C in 10 mM HEPES, pH 7.5, 150 mM NaCl and 3%
isopropanol, with a differential power of 10 μcal s−1 and stirring at 750 rpm.
Experiments consisted of an initial test injection of 0.4 μL, followed 150 s later by
18 injections of 2 μL, spaced 150 s apart. Owing to the low solubility of cholesterol,
a PEG-cholesterol was used for afﬁnity measurements. HHIPN was dialysed
against 0.15 M NaCl, 10 mM HEPES and 3% isopropanol, ﬁnal pH 7.5. Lyophilized
PEG-cholesterol and PEG200 were resuspended in dialysis solution to a concentration of 1 mM. Protein concentrations were determined from the absorbance
at 280 nm using calculated molar extinction coefﬁcients. Cell concentrations of
9 μM HHIPN protein and syringe concentrations of 1 mM PEG-cholesterol or
PEG200 were used for all experiments. Thermograms were integrated and corrected for heats of dilution using PEAQ-ITC analysis software (Malvern). Isotherms were ﬁtted with the A + B ⇌ AB model, where cell and syringe
concentrations and baselines of each experiment were ﬁtted locally. All ﬁgures were
prepared using PEAQ-ITC analysis software (Malvern).
Immunoﬂuorescence microscopy. HEK 293 T cells were seeded at a concentration of 10,000 cells mL−1 in poly-D-lysine coated 35 mm dishes (MatTek)
and incubated at 37 °C, 5% CO2 for 18 h. Media was exchanged to reduce serum
concentration from 10 to 2% and cells were transfected with 2 μg DNA of HAtagged constructs using lipofectamine at a ratio of 1:2. 6 hours following
transfection, cellular growth medium was further lowered to 0.5% serum and
cells were further incubated for 2 days. Media was removed and cells were
washed with PBS before ﬁxation for 15 min with 3% para-formaldehyde and
quenching in 0.3 M glycine for 3 min. Fixed cells were stored overnight at 4 °C in
PBS. For the staining process, ﬁxed cells were blocked for 10 min using 1% BSA/
PBS, before HA tag probing using a Mouse HA Epitope Tag Antibody (Thermo
Fisher) at 1 μg mL−1 in 1% BSA/PBS at 25 °C for 1 h. Cells were washed in PBS 3
times for 10 min, before incubation with an Alexa Fluor® 633-conjugated Goat
anti-Mouse IgG antibody (λex: 633 nm; λem: 647 nm) (Thermo Fisher) at a
concentration of 2 μg mL−1 in 1% BSA/PBS for 1 h at 25 °C. Excess antibody was
removed via washing 3 times in PBS for 10 min, with one ﬁnal wash containing
0.5 μg mL−1 Hoechst 33342 nuclear stain (λex: 353 nm; λem: 483 nm)98. Immunoﬂuorescence was detected using a Leica TCS SP8 WLL Confocal SMD
Microscope. Images were processed in Fiji99.
Multiangle light scattering (MALS). A total of 100 μL protein samples were
injected onto an S200 10/30 column (GE Healthcare) equilibrated in a running
buffer of 10 mM HEPES pH 7.5, 150 mM NaCl over a concentration range of
48–192 μM. A Wyatt Dawn HELEOS-II MALS detector and Wyatt Optilab rEX
refractive index monitor recorded both the refractive index and light scattering
once separated via SEC. ASTRA software (Wyatt Technology) was used for data
analysis.
HHIP-C mutant heparin afﬁnity chromatography. HHIP-C constructs (200 μg/
run) were loaded onto a 1 mL heparin column (HiTrap heparin HP, GE Healthcare) in a buffer of 10 mM HEPES pH 7.5, 40 mM NaCl (~5 mS/cm) and eluted
over 30 column volumes with a gradient of elution buffer up to 10 mM HEPES pH
7.5, 1000 mM NaCl (~87 mS/cm). Elution was followed by absorption at 280 nm.
The HHIP-C Glu mutant eluted from the column at ~240 mM NaCl, 10 mM

HEPES pH 7.5 (22 mS/cm). The dual GAG site mutant (ΔGAG sites 1 + 2) eluted
at ~320 mM NaCl, 10 mM HEPES pH 7.5 (29 mS/cm). The β-propeller interface
GAG mutant (ΔGAG site 1) eluted at ~400 mM NaCl, 10 mM HEPES pH 7.5 (36
mS/cm) and the EGF interface GAG mutant (ΔGAG site 2) eluted at ~410 mM
NaCl, 10 mM HEPES pH 7.5 (37 mS/cm). Wild-type HHIP-C eluted at ~450 mM
NaCl, 10 mM HEPES pH 7.5 (40 mS/cm).
Generation of NIH/3T3 Extl3−/− ﬁbroblasts. Clonal EXTL3 knockout cell lines
were generated using a double-cut CRISPR strategy. Guides were cloned into
pSpCas9(BB)-2A-GFP (PX458; Addgene #48138) and pSpCas9(BB)-2A-mCherry.
Plasmids were co-transfected into NIH/3T3 Flp-Ins using X-tremeGENE 9
(Roche). Four days post-transfection, GFP and mCherry double-positive single
cells were sorted into 96-well plates using a Sony Cell Sorter Model SH800S. To
screen clonal cell lines, we used PCR to detect successful excision of the genomic
DNA between the two sgRNA cut sites (Supplementary Fig. 12, Supplementary
Table 3).
HS20 cell staining of CRISPR generated EXTL3 knockouts. To conﬁrm that
Extl3−/− NIH/3T3 cells had reduced cell surface Heparan Sulfate Proteoglycans
(HSPGs), we stained intact cells with a previously characterized HS20 scFv antibody (fused to a 1D4 epitope tag), which recognizes a Heparan Sulphate chains
attached to HSPGs54,55. Cells were trypsinized and resuspended in Staining Buffer
(SB: PBS + 2% BSA + 0.05% sodium azide) at a density of 500,000 cells/100 μL
buffer. Cells were then spun down and resuspended in SB with 5% donkey serum.
Following a ten-minute room temperature incubation, cells were spun down,
resuspended in 50 μL SB containing HS20-1D4 tag (1:20.83 dilution), and incubated for 30 minutes at 4 °C. Samples were then washed twice with SB, before being
incubated for 30 min at 4 °C in anti-1D4 monoclonal antibody diluted in SB (1:500;
The University of British Columbia). After incubation with anti-1D4 antibody, cells
were again washed twice with SB. Samples were then incubated in donkey antimouse antibody coupled to Alexa Fluor 594 diluted in SB (1:500; ThermoFisher
Scientiﬁc A-21203) for 30 minutes at 4 °C. Cells were then washed three times with
SB before being resuspended in PBS for ﬂow cytometry analysis. Flow cytometry
was performed on a BD Acuri C6 Flow Cytometer using a 552 nm laser for
excitation and a 610/20 nm bandpass ﬁlter to collect emitted light. Forward and
side scatter plots were used to select a population of live, mostly single cells, which
were then analyzed. A population of at least 7500 selected cells was analyzed for
each sample.
HH signalling assay. Gli1 mRNA measurements were used as a readout for HH
pathway activation and were performed as in7. Brieﬂy, NIH/3T3 cells (ATCC,
CRL-1658) were grown to conﬂuency and then serum-starved for 24 h via
reduction of serum to 0.5% NBCS. The HH pathway was either induced by adding
50 nM puriﬁed ShhNC24II12,100, or NIH/3T3 cells were co-cultured with the fulllength HH-producing human cell line PANC-1 (ATCC, CRL-1469)48, with addition of HHIP-C constructs or HHIP-ΔHx at 100 nM in each case. For HH pathway
stimulation by the palmitoylated N-terminal ShhN peptide (Palm-ShhN15), peptides were added at 10 µM and HHIP-ΔHx at 1 µM (n = 2). Reverse transcription
quantitative PCR (RT-qPCR) was carried out with the Power SYBR® Green Cellsto-CTTM kit (Life Technologies) according to manufacturer’s instructions. Every
experiment was performed with two biological replicates and three technical
replicates and results were calculated according to the ΔΔCT method and maximal
pathway activation was normalised to 100. The PCR primers for Gli1 (forward
primer, 5′-ccaagccaactttatgtcaggg-3′; reverse primer, 5′-agcccgcttctttgttaatttga-3′);
and Gapdh (forward primer, 5′-agtggcaaagtggagatt-3′; reverse primer, 5′-gtggagtcatactggaaca-3′) are speciﬁc for murine DNAs.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
Atomic coordinates and structure factors for HHIP-N:SOS, HHIP-N apo, HHIPC:heparin and HHIP-C:SOS have been deposited in the Protein Data Bank (PDB)
(www.rcsb.org) under accession numbers 7PGK, 7PGL, 7PGM and 7PGN, respectively.
Any other data supporting the ﬁndings of this manuscript are available from the
corresponding author upon reasonable request. Source data are provided with this paper.
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